IN8BIO, INC.
corporate_fare Company Profile
IN8BIO, INC. (NASDAQ:INAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for INAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 9/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for INAB spans 10-Q, 8-K, 424B5, SCHEDULE 13D/A.
Recent high-impact activity:
- IN8bio Q2 2026: Cash Only Through April 2027, Going Concern Warning Reiterated
- IN8bio's DeltEx DRI Doubles Progression-Free Survival in Glioblastoma, Published in JCO
- IN8bio's Glioblastoma Therapy Extends Survival to Over 19.5 Months, Nearly Doubling Standard of Care
- IN8bio Launches $2.8M At-The-Market Offering to Raise Capital
- IN8bio Establishes New $2.8M At-The-Market Offering Agreement, Replaces Previous Program
Financial Snapshot
Short Interest & Short Volume
2.21 days to coverFINRA reported short interest of 63,110 shares in INAB as of the September 15, 2026 settlement, a 30.5% decrease from the prior period — about 2.2 days to cover at its recent average daily volume. On October 2, 2026, 33.7% of INAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for INAB, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.
At-The-Market Offering Launched · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →